ClinicalTrials.gg
CompletedNCT03924856KEYNOTE-866Updated Oct 8, 2026

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A Phase 3 interventional study of Pembrolizumab and Gemcitabine in Bladder Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 175 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Updated Oct 8, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
907
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing pembrolizumab in Urinary Bladder Neoplasms — 13 open to participants now, 20 under way, 5 of them phase 3. pembrolizumab · Urinary Bladder Neoplasms.

Enrollment
Largest of 39
907 · median 60
Started
2019
with 3 others
Phase 3
8 of 39
2 open now
Registered
19th of 39
by date
Lead sponsor
7 of 39
Merck Sharp & Dohme LLC

Among the 39 studies testing pembrolizumab in Urinary Bladder Neoplasms, this one has the largest enrollment, is one of 4 that started in 2019, is one of 8 in phase 3, and was the 19th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

13 of the 39 studies testing pembrolizumab in Urinary Bladder Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing pembrolizumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

03

Conditions studied

  • Bladder Cancer

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
  • Pembrolizumab (MK-3475)
  • Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%) urothelial histology.
  • Have clinically non- bladder cancer (N≤1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI)) of the chest/abdomen/pelvis.
  • Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND).
  • Have (ECOG) Performance Status of 0 or 1.
  • Have adequate organ function.
  • Male and female participants are eligible to participate if they agree to the use as per study protocol.

Exclusion criteria

Exclusion Criteria:

  • Has a known additional that is progressing or has required active anti-cancer treatment ≤3 years of study randomization with certain exceptions.
  • Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • Has ≥N2 disease or disease (M1) as identified by imaging.
  • Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol.
  • Has received prior systemic anticancer therapy including agents within 3 years of randomization or any radiotherapy to the bladder.
  • Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC.
  • Has received a live or within 30 days before the first dose of study intervention.
  • Has a diagnosis of immunodeficiency or has a known history of (HIV) infection, infection or known active infection.
  • Has a known psychiatric or substance abuse disorder.
  • Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
907 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Gemcitabine + Cisplatin + Surgery

    Participants received 4 preoperative cycles of pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative pembrolizumab.

    Drug: Pembrolizumab · Drug: Gemcitabine · Drug: Cisplatin · Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])

  • Placebo comparator
    Placebo + Gemcitabine + Cisplatin + Surgery

    Participants received 4 preoperative cycles of placebo to pembrolizumab PLUS gemcitabine PLUS cisplatin, followed by surgery, followed by up to 13 cycles of postoperative placebo to pembrolizumab.

    Drug: Gemcitabine · Drug: Cisplatin · Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]) · Drug: Placebo

Interventions

  • Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle

    Also known as: MK-3475

  • Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle

  • Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle

  • ProcedureSurgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])

    Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.

  • DrugPlacebo

    Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS)

    EFS is defined as the time from randomization to the first occurrence of any of the following events: progression of disease that precludes RC surgery; failure to undergo RC surgery in participants with residual disease and any radiographical disease present; gross residual disease left behind at the time of surgery; local or distant recurrence based on investigator assessments and/or biopsy, or death due to any cause.

    Time frame: Up to approximately 60 months

Secondary outcomes

  1. Pathologic Complete Response (pCR) Rate

    pCR rate is defined as the percentage of participants having pCR. pCR is defined as absence of viable tumor (pT0N0) in examined tissue from RC and PLND, as assessed by blinded independent central review (BICR).

    Time frame: Up to approximately 72 months

  2. Overall Survival (OS)

    Overall survival is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 72 months

  3. Disease-Free Survival (DFS)

    DFS is defined as the time from post-surgery baseline scan until the first occurrence of either local or distant recurrence as assessed by investigator by CT or MRI and/or computerized tomography (CT) or magnetic resonance imaging (MRI) and or biopsy or death from any cause.

    Time frame: From approximately 20 weeks up to approximately 72 months

  4. Pathologic Downstaging (pDS) Rate

    pDS rate is defined as the percentage of participants having pDS. pDS is defined as participants with a tumor classification of \<pT2 (includes pT0, pTis, pTa, pT1) and N0 in examined tissue from RC plus PLND as assessed by BICR.

    Time frame: Up to approximately 72 months

  5. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to approximately 72 months

  6. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to approximately 12 months

  7. Number of Participants Who Experienced Perioperative Complications

    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.

    Time frame: Up to approximately 12 months

  8. Change in Patient-Reported Outcomes from Baseline in Total Score of Functional Assessment of Cancer Therapy - General (FACT-G)

    The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score can range from 0 to 108.

    Time frame: Baseline, Up to approximately 72 months

  9. Change in Patient-Reported Outcomes from Baseline in Total Score of FACT-Bladder- (FACT-BI-Cys)

    Total Score of FACT BI-Cys is the sum of FACT-G total score and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys can range from 0 to 168.

    Time frame: Baseline, Up to approximately 72 months

  10. Change in Patient-Reported Outcomes from Baseline in FACT-BI-Cys-Trial Outcome Index (TOI)

    FACT-Bl-Cys Trial Outcome Index (TOI) is the sum of FACT-G PWB score, FWB score, and FACT-Bl-Cys score. FACT-Bl-Cys contains 17 items on the bowel, bladder, and sexual symptoms following cystectomy. The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0 to 4, with higher scores indicating higher HRQoL. The total score of FACT-Bl-Cys TOI can range from 0 to 116.

    Time frame: Baseline, Up to approximately 72 months

  11. Change in Patient-Reported Outcomes from Baseline in EuroQol Five-Dimensional Questionnaire (EQ-5D-5L) Visual Analog Score (VAS)

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

    Time frame: Baseline, Up to approximately 72 months

  12. Time to Deterioration (TTD) in the Total Score of FACT-G

    The FACT-G is a health-related quality of life (HRQoL) 27-item questionnaire in patients being treated for cancer. The FACT-G subscales include Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), and Functional Well-Being (FWB). All items are scored on a 5-point Likert scale of 0-4, with higher scores indicating higher HRQoL. TTD is defined as the time from baseline to the first onset of patient-reported outcomes (PRO) deterioration. For the FACT-G questionnaire, deteriorations are defined as a decrease of 7 points or more (out of 108) from baseline in total score.

    Time frame: Up to approximately 72 months

  13. TTD in EQ-5D-5L VAS

    The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and includes 5 health state dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In the EQ-5D-5L VAS, the participant rates his or her general state of health at the time of the assessment on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. TTD is defined as the time from baseline to the first onset of PRO deterioration. For the EQ 5D-5L, deterioration is defined as a decrease of 7 points or more from baseline in the VAS.

    Time frame: Up to approximately 72 months

07

Study locations

175 sites
  • Scripps MD Anderson ( Site 0010)
    La Jolla, California 92037, United States
  • Providence Saint John's Health Center ( Site 0075)
    Santa Monica, California 90404, United States
  • Georgetown University Medical Center ( Site 0022)
    Washington D.C., District of Columbia 20007, United States
  • AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005)
    Orlando, Florida 32804, United States
  • Parkview Cancer Institute ( Site 0077)
    Fort Wayne, Indiana 46845, United States
  • Indiana University Melvin and Bren Simon Cancer Center ( Site 0004)
    Indianapolis, Indiana 46202, United States
  • Ochsner Medical Center ( Site 0049)
    New Orleans, Louisiana 70121, United States
  • New England Cancer Specialists ( Site 0070)
    Scarborough, Maine 04074, United States
  • UMass Memorial Medical Center ( Site 0051)
    Worcester, Massachusetts 01655, United States
  • Henry Ford Hospital ( Site 0039)
    Detroit, Michigan 48202, United States
  • Mercy Hospital Saint Louis ( Site 0064)
    St Louis, Missouri 63141, United States
  • Morristown Medical Center ( Site 0015)
    Morristown, New Jersey 07960, United States
  • UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045)
    Albuquerque, New Mexico 87106, United States
  • New York University Perlmutter Cancer Center ( Site 0008)
    New York, New York 10016, United States
  • University Hospitals Cleveland Medical Center ( Site 0038)
    Cleveland, Ohio 44106, United States
  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021)
    Tulsa, Oklahoma 74146, United States
  • Portland VA Medical Center ( Site 0084)
    Portland, Oregon 97239, United States
  • Allegheny General Hospital ( Site 0048)
    Pittsburgh, Pennsylvania 15212, United States
  • MD Anderson Cancer Center ( Site 0063)
    Houston, Texas 77030, United States
  • Central Texas Veterans Healthcare System ( Site 0057)
    Temple, Texas 76504, United States
  • Inova Schar Cancer Institute ( Site 0007)
    Fairfax, Virginia 22031, United States
  • Northwest Medical Specialties, PLLC ( Site 0061)
    Puyallup, Washington 98373, United States
  • Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033)
    Seattle, Washington 98109, United States
  • Charleston Area Medical Center ( Site 0023)
    Charles Town, West Virginia 25304, United States
  • Mid North Coast Cancer Institute ( Site 1256)
    Port Macquarie, New South Wales 2444, Australia
  • Southside Cancer Care Centre ( Site 1252)
    Sydney, New South Wales 2228, Australia
  • Cairns Base Hospital ( Site 1257)
    Cairns, Queensland 4870, Australia
  • Eastern Health ( Site 1255)
    Box Hill, Victoria 3128, Australia
  • Peninsula Health Frankston Hospital ( Site 1258)
    Frankston, Victoria 3199, Australia
  • UZ Brussel ( Site 0358)
    Brussels, Bruxelles-Capitale, Region de 1090, Belgium
  • Jessa Ziekenhuis ( Site 0360)
    Hasselt, Limburg 3500, Belgium
  • CHU UCL Namur Site de Godinne ( Site 0354)
    Yvoir, Namur 5530, Belgium
  • O.L.V. Ziekenhuis Aalst ( Site 0356)
    Aalst, Oost-Vlaanderen 9300, Belgium
  • AZ Maria Middelares Gent ( Site 0353)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Tom Baker Cancer Centre ( Site 0100)
    Calgary, Alberta T2N 4N2, Canada
  • Nova Scotia Health Authority ( Site 0109)
    Halifax, Nova Scotia B3H 1V7, Canada
  • Kingston Health Sciences Centre ( Site 0103)
    Kingston, Ontario K7L 2V7, Canada
  • Lakeridge Health ( Site 0104)
    Oshawa, Ontario L1G 2B9, Canada
  • Sunnybrook Research Institute ( Site 0110)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0107)
    Toronto, Ontario M5G 2M9, Canada
  • CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0105)
    Montreal, Quebec H1T 2M4, Canada
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
    Québec, Quebec G1J 1Z4, Canada
  • Rigshospitalet University Hospital ( Site 0401)
    Copenhagen, Capital Region 2100, Denmark
  • Herlev og Gentofte Hospital. ( Site 0402)
    Herlev, Capital Region 2730, Denmark
  • Odense Universitetshospital ( Site 0403)
    Odense, Region Syddanmark 5000, Denmark
  • CHU de Bordeaux- Hopital Saint Andre ( Site 0456)
    Bordeaux, Aquitaine 33075, France
  • Centre Leon Berard ( Site 0465)
    Lyon, Auvergne 69373, France
  • Centre Francois Baclesse ( Site 0459)
    Caen, Calvados 14075, France
  • Centre Armoricain de Radiotherapie Imagerie medicale et Oncologie ( Site 0457)
    Plérin, Cotes-d Armor 22190, France
  • Hopital Foch ( Site 0483)
    Suresnes, Hauts-de-Seine 92150, France
  • CHU de Montpellier - Hopital Saint-Eloi ( Site 0469)
    Montpellier, Languedoc-Roussillon 34295, France
  • Institut de Cancerologie de l Ouest Site Paul Papin ( Site 0453)
    Angers, Maine-et-Loire 49000, France
  • Hopital Robert Schuman ( Site 0452)
    Metz, Moselle 57070, France
  • Centre Jean Perrin ( Site 0460)
    Clermont-Ferrand, Puy-de-Dome 63011, France
  • Clinique Victor Hugo ( Site 0463)
    Le Mans, Sarthe 72000, France
  • CHU de Rouen ( Site 0493)
    Rouen, Seine-Maritime 76031, France
  • Institut Sainte Catherine ( Site 0454)
    Avignon, Vaucluse 84918, France
  • Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502)
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Universitaetsklinikum Erlangen ( Site 0505)
    Erlangen, Bavaria 91058, Germany
  • Universitaetsklinikum Carl Gustav Carus ( Site 0519)
    Dresden, Saxony 01307, Germany
  • Universitaetsklinikum Magdeburg A.o.R. ( Site 0516)
    Magdeburg, Saxony-Anhalt 39120, Germany
  • Universitaetsklinikum Schleswig-Holstein-Campus Lubeck ( Site 0512)
    Lübeck, Schleswig-Holstein 23538, Germany
  • Charite Universitaetsmedizin Berlin ( Site 0515)
    Berlin, 10117, Germany
  • Vivantes Klinikum am Urban ( Site 0522)
    Berlin, 10967, Germany
  • Pecsi Tudomanyegyetem AOK ( Site 1009)
    Pécs, Baranya 7624, Hungary
  • SZTE Szent-Gyorgyi Albert Klinikai Kozpont ( Site 1010)
    Szeged, Csongrád megye 6720, Hungary
  • Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1002)
    Szolnok, Jász-Nagykun-Szolnok 5004, Hungary
  • Bajcsy Zsilinszki Korhaz es Rendelointezet ( Site 1001)
    Budapest, 1106, Hungary
  • Debreceni Egyetem Klinikai Kozpont ( Site 1006)
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz ( Site 1012)
    Győr, 9023, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1007)
    Kaposvár, 7400, Hungary
  • Cork University Hospital ( Site 0722)
    Cork, T12 DC4A, Ireland
  • Tallaght University Hospital ( Site 0710)
    Dublin, D24 DH74, Ireland
  • University Hospital Waterford ( Site 0723)
    Waterford, X91ER8E, Ireland
  • Ha Emek Medical Center ( Site 0808)
    Afula, 1834111, Israel
  • Soroka Medical Center ( Site 0806)
    Beersheba, 8410101, Israel
  • Rambam Health Care Campus-Oncology Division ( Site 0802)
    Haifa, 3109601, Israel
  • Shaare Zedek Medical Center ( Site 0809)
    Jerusalem, 9103102, Israel
  • Hadassah Ein Kerem Medical Center ( Site 0810)
    Jerusalem, 9112001, Israel
  • Meir Medical Center ( Site 0803)
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center ( Site 0804)
    Petah Tikva, 4941492, Israel
  • Sheba Medical Center ( Site 0801)
    Ramat Gan, 5265601, Israel
  • Sourasky Medical Center ( Site 0807)
    Tel Aviv, 6423906, Israel
  • Yitzhak Shamir Medical Center ( Site 0805)
    Ẕerifin, 7030001, Israel
  • Policlinico Gemelli di Roma ( Site 0558)
    Roma, Abruzzo 00168, Italy
  • Policlinico di Modena ( Site 0553)
    Modena, Emilia-Romagna 41124, Italy
  • A.O.U. Policlinico Vittorio Emanuele - Presidio Gaspare Rodolico ( Site 0559)
    Catania, 95123, Italy
  • Istituto Nazionale Studio e Cura dei Tumori ( Site 0551)
    Milan, 20133, Italy
  • Istituto Nazionale Per Lo Studio E La Cura Dei Tumori ( Site 0552)
    Naples, 80131, Italy
  • Fondazione Salvatore Maugeri IRCCS. ( Site 0554)
    Pavia, 27100, Italy
  • Azienda Ospedaliera San Camillo Forlanini ( Site 0560)
    Roma, 00152, Italy
  • Azienda Ospedaliera Santa Maria Terni ( Site 0557)
    Terni, 05100, Italy
  • Hirosaki University Hospital ( Site 1502)
    Hirosaki, Aomori 036-8563, Japan
  • National Cancer Center Hospital East ( Site 1504)
    Kashiwa, Chiba 2778577, Japan
  • Ehime University Hospital ( Site 1508)
    Tōon, Ehime 791-0295, Japan
  • Sapporo Medical University Hospital ( Site 1501)
    Sapporo, Hokkaido 060-8543, Japan
  • University of Tsukuba Hospital ( Site 1503)
    Tsukuba, Ibaraki 305-8576, Japan
  • Yokosuka Kyosai Hospital ( Site 1509)
    Yokosuka, Kanagawa 238-8558, Japan
  • Nara Medical University Hospital ( Site 1510)
    Kashihara, Nara 634-8522, Japan
  • Saitama Medical University International Medical Center ( Site 1505)
    Hidaka, Saitama 350-1298, Japan

Showing the first 100 of 175 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19. PubMed 34008425 ↗

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jan 2026, 79 months.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 79 months is above that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → May 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2019
First posted
Apr 23, 2019
StartActual
Jun 13, 2019
Primary completionActual
Jan 26, 2026
CompletionActual
May 18, 2026was Jun 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jun 11, 2026→May 18, 2026
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Study completion Jun 11, 2026→May 18, 2026
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03924856
Responsible party
Sponsor
First posted
Apr 23, 2019
Start date
Jun 13, 2019
Primary completion
Jan 26, 2026
Completion
May 18, 2026
Last update
Oct 8, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion